We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. ADC Therapeutics SA (ADCT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
ADC Therapeutics SA is a member of our Medical group, which includes 891 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ADC Therapeutics SA is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ADCT's full-year earnings has moved 34.3% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ADCT has returned about 9.4% since the start of the calendar year. In comparison, Medical companies have returned an average of -5.1%. This means that ADC Therapeutics SA is performing better than its sector in terms of year-to-date returns.
Biogen Inc. (BIIB - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 1.7%.
For Biogen Inc., the consensus EPS estimate for the current year has increased 4.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, ADC Therapeutics SA is a member of the Medical - Biomedical and Genetics industry, which includes 436 individual companies and currently sits at #95 in the Zacks Industry Rank. This group has gained an average of 3.1% so far this year, so ADCT is performing better in this area. Biogen Inc. is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on ADC Therapeutics SA and Biogen Inc. as they attempt to continue their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. ADC Therapeutics SA (ADCT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
ADC Therapeutics SA is a member of our Medical group, which includes 891 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ADC Therapeutics SA is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ADCT's full-year earnings has moved 34.3% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ADCT has returned about 9.4% since the start of the calendar year. In comparison, Medical companies have returned an average of -5.1%. This means that ADC Therapeutics SA is performing better than its sector in terms of year-to-date returns.
Biogen Inc. (BIIB - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 1.7%.
For Biogen Inc., the consensus EPS estimate for the current year has increased 4.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, ADC Therapeutics SA is a member of the Medical - Biomedical and Genetics industry, which includes 436 individual companies and currently sits at #95 in the Zacks Industry Rank. This group has gained an average of 3.1% so far this year, so ADCT is performing better in this area. Biogen Inc. is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on ADC Therapeutics SA and Biogen Inc. as they attempt to continue their solid performance.